NOTTINGHAM, UK – June 4th, 2025 – 4D Medicine Limited, a pioneering developer of advanced biomaterials for orthopaedic and surgical applications, is pleased to announce its participation as an exhibitor at the Orthopaedic Manufacturing & Technology Exposition and Conference (OMTEC) 2025, taking place June 18–19 at the Donald E. Stephens Convention Center in Chicago, Illinois.

Attendees are invited to connect with 4D Medicine at Booth #558, where the company will be showcasing 4Degra®- its innovative bioabsorbable polymer platform that offers unprecedented performance in tissue repair and regeneration. This cutting-edge biomaterial, featuring novel polycarbonate urethane chemistry, is designed to meet the evolving needs of the orthopaedic, spine, and trauma markets. 

4D Medicine will be actively seeking sales channel partners for the Degrafix Interference Screw that delivers improved biocompatibility and more predictable resorption to increase surgeon confidence in long-term procedural success. The DegraFix interference Screw is the first product in a potential portfolio of improved soft tissue fixation devices.

“We are excited to engage with industry leaders and investors at OMTEC 2025,” said Phil Smith, CEO of 4D Medicine Limited. “Our materials offer unique advantages in terms of processibility, biocompatibility, and regenerative potential. We look forward to exploring strategic partnerships that will accelerate commercialization and expand clinical impact.”

Attendees are encouraged to schedule meetings in advance by contacting the 4D Medicine business development team at info@4dmedicine.co.uk.

For more information about 4D Medicine Limited and its novel biomaterial platform, please visit www.4dmedicine.co.uk.

ENDS

NOTTINGHAM, UK. 3rd April, 2025 – 4D Biomaterials Ltd, the materials manufacturing subsidiary of 4D Medicine Ltd, a UK university spin-out company developing next-generation bioresorbable medical devices, today announced it has achieved ISO 13485:2016 certification from The British Standards Institution (BSI). 

This globally recognised quality standard for medical device manufacturing marks a critical milestone in the company’s path to market, demonstrating high quality, low risk and customer-focused manufacturing capability. 

The certification confirms that 4D Biomaterials Ltd operates under a quality management system that meets stringent international regulatory requirements — a core prerequisite for the raw materials used in medical devices seeking regulatory approvals, clinical deployment, and global distribution. As such, certification significantly de-risks the company’s commercial strategy. 

Phil Smith, CEO of parent company, 4D Medicine Ltd commented:

“This achievement is a pivotal moment for our materials manufacturing business. ISO 13485 certification validates its operational systems and sends a clear signal to partners and investors: we are ready to scale. It also reflects the maturity of our technology platform, the discipline of our team, and our commitment to executing a high-quality commercialisation strategy.”

This milestone positions 4D to accelerate the development of commercial partnerships, regulatory approvals, and revenue-generating opportunities as it advances its differentiated product pipeline toward global markets.

ENDS

NOTTINGHAM, UK. March 11th, 2025 – 4D Medicine Ltd, an emerging innovator in the biomaterials and medical device sector, is proud to announce the launch of its newly redesigned corporate website, www.4dmedicine.co.uk.

The site is designed to offer a comprehensive resource for investors, strategic partners, and healthcare professionals, highlighting the company’s groundbreaking 4Degra® bioabsorbable polymer technology and its potential to transform the medical device industry.

The new website offers information on the unique properties of 4Degra®, a next-generation bioabsorbable polymer developed to improve patient outcomes in medical device applications. 4Degra®’s unparalleled versatility and biocompatibility make it an ideal material for a wide range of devices, including those used in musculoskeletal repair, soft tissue regeneration and drug-delivery.

“4Degra® represents the next evolution in bioabsorbable materials, and this website serves as an essential tool to communicate the exciting opportunities that lie ahead for investors and collaborators,” said Phil Smith, CEO of 4D Medicine. 

“We’ve designed the site to not only inform but to also demonstrate the potential impact our technology can have in improving surgical outcomes and improving lives.”

Key features of the new website include:

The launch of this website underscores 4D Medicine’s commitment to transparency, collaboration, and ongoing innovation. The company is poised to lead the way in delivering solutions that enhance patient care and create lasting value for its partners and stakeholders.

ENDS

LONDON, UK. February 5th, 2025 – Modern Synthesis, a biotechnology company pioneering the development of microbially-derived biomaterials, today announces the successful close of a $5.5 million funding round. The oversubscribed round was led by Extantia Capital, with participation from Artesian and Collaborative Fund. This investment will enable Modern Synthesis to expand production at its pilot facility and service more leading fashion brands on its growing waitlist. 

Industry research shows that fashion brands trying to comply with mounting decarbonisation and climate regulations will face a 133 million tonne shortfall of low-impact raw materials by 2030. Modern Synthesis’ technology enables brands to reduce this shortfall by proactively adjusting their preferred raw materials mix whilst delivering new looks, feels, and material functions.

To make their biobased materials, Modern Synthesis transforms nanocellulose – a natural fermentation-derived fibre – into durable, high quality alternatives to animal leather, ‘vegan’ leather, and plastic-based coated textiles. The company’s scalable, proprietary process leverages advanced material science to build upon the innate strength and versatility of nanocellulose, a naturally derived polymer which is eight times stronger than steel at a nanofibre level. The resulting materials are free from petrochemicals and toxic ingredients, and offer reduced environmental impact compared to incumbent textiles.

CEO and Co-Founder of Modern Synthesis, Jen Keane, said: “Having demonstrated unprecedented material performance without plastic, we’re primed to offer the fashion market a material solution that can both captivate consumers and unlock a path to circularity. This investment gives us the capacity to work with more brands as we continue to uncover new use cases for the technology.”

In September 2023, Modern Synthesis unveiled a prototype handbag in collaboration with Danish fashion brand GANNI; the companies are jointly working towards a commercial launch of GANNI’s Bou Bag in Modern Synthesis’ biomaterial. Despite the demand from the industry, commercially available sustainable textiles represent less than 5% of the $1 trillion global apparel textile market. With more than 35 new sustainability-linked regulations slated to reshape the industry in the next few years, fashion and apparel brands that fail to adapt their material portfolios could face significant financial risks, with up to 8% of EBIT potentially at stake, according to BCG analysis.

Yair Reem, Partner at Extantia Capital, said: “The first thing that struck us was how this material rivals traditional leathers in look and feel, but can also offer something entirely new that excites designers. Jen’s deep expertise in fashion and design, combined with Ben’s tech-savvy brilliance, has created a game-changing solution that redefines what’s possible with sustainable, high-performance materials. Modern Synthesis represents the future of industry – delivering better, more cost-effective and resilient materials that also happen to be green.”

Alexandra Clunies-Ross, Partner at Artesian Investments, added: “We are delighted to partner with Modern Synthesis in their mission to mainstream biobased materials. Our investment decision was driven by the company’s potential to revolutionise traditional manufacturing processes, and drive real impact at scale. At Artesian, we believe that early-stage investment in innovative technology companies like Modern Synthesis is crucial in addressing the climate crisis.”

The added support of leading climate-focused investors will enable Modern Synthesis to address the urgent need for lower-impact materials in the fashion industry, while paving the way for future expansion into the footwear and automotive markets.

ENDS

LONDON, England, September 20, 2023 – 

Modern Synthesis, a biotechnology company at the forefront of sustainable material innovation, and GANNI, the visionary Danish fashion brand, have joined forces to reimagine the iconic GANNI ‘Bou’ handbag in a new biomaterial. Their latest pilot of the Bou Bag showcases the natural beauty and versatility of Modern Synthesis’ bacterial nanocellulose materials, brought to life in GANNI’s signature hexagonal silhouette. The companies are jointly working to make this bag commercially available by early 2025. 

The pilot marks an exciting chapter in GANNI’s Fabrics of the Future programme, which challenges the use of conventional materials in fashion and elevates responsible alternatives in collaboration with pioneering start ups.

Created with bacterial nanocellulose – a particularly strong and fine form of cellulose derived from bacterial fermentation – the featured biotextile is naturally animal and plastic free and offers a desirable alternative to virgin leathers and plastic-based synthetics. The Modern Synthesis x Ganni Bou Bag marks another critical step in Ganni’s quest to redefine responsible luxury by continuously championing innovation in materials. Working with Modern Synthesis to reimagine the ‘Bou’ further underscores their commitment to phasing out virgin leather from GANNI products by 2023. 

The Modern Synthesis x Ganni Bou Bag will take centre stage at the upcoming Material Matters fair, showing from September 20-23 during the highly anticipated London Design Festival. By presenting this one-of-a-kind piece at the capital’s leading design festival, both Modern Synthesis and Ganni hold a mirror up to the potential of design and provide a glimpse into the promising future of biomaterials within the commercial realm.

Lauren Bartley, Sustainability & CSR Director, GANNI, stated,

“GANNI is on track to phase out all virgin leather by the end of this year,  which has been a radical goal for us. But the work doesn’t stop here. Working and trialing with partners like Modern Synthesis to develop more responsible and durable leather alternatives is crucial for us. Doing so enables us to create high-quality design products in lower-impact materials – changing the future of fabrics as we know them today. By partnering with Modern Synthesis to develop our iconic Bou Bag from bacteria, we get another step closer to our goal of having 10% of materials coming from our ‘Fabrics of The Future’ by 2025 – and we can’t wait to see what else we can make with Modern Synthesis’ technology.”

Jen Keane, CEO of Modern Synthesis, explained, “Collaborating with GANNI on the Bou Bag has allowed us to showcase the viability of bacterial cellulose-based materials in real-world applications. These one-off showcase pieces are pivotal in evaluating a material’s workability and appeal to both designers and consumers – which paves the way for its eventual integration into everyday fashion. Our pilot is a testament to the potential of sustainable materials in transforming the fashion industry, and we’re excited to grow our partnership.”

As the bacteria-based Bou Bag’s debut captivates audiences at the Material Matters fair, Modern Synthesis and GANNI are confident that this pilot / trial will serve as a beacon for other fashion brands to explore sustainable alternatives. By pushing the boundaries of design and material capability, the two entities are propelling the industry towards a more conscious and creative future.